Lyell Immunopharma (LYEL) closed at $14.30 on November 13, 2026, down 8.6% from the previous close, on volume of 221,024 shares (30-day average 211,380).
Data as of November 13, 2026.
13-Nov-2026
Bank of America Securities Reaffirms Their Sell Rating on Lyell Immunopharma (LYEL)
TipRanks (Mon, 16-Nov 5:56 AM ET)
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
Globe Newswire (Wed, 4-Nov 9:02 AM ET)
Globe Newswire (Wed, 4-Nov 9:01 AM ET)
Lyell Immunopharma To Participate in November Investor Events
Globe Newswire (Mon, 2-Nov 8:00 AM ET)
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
Globe Newswire (Mon, 14-Sep 7:00 AM ET)
Globe Newswire (Thu, 10-Sep 4:05 PM ET)
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Lyell Immunopharma trades on the NASDAQ stock market under the symbol LYEL.
As of November 13, 2026, LYEL stock price declined to $14.30 with 221,024 million shares trading.
LYEL has a beta of 1.26, meaning it tends to be more sensitive to market movements. LYEL has a correlation of 0.03 to the broad based SPY ETF.
LYEL has a market cap of $350.41 million. This is considered a Small Cap stock.
Last quarter Lyell Immunopharma reported $3,000 in Revenue and -$1.86 earnings per share. This fell short of revenue expectation by $-290 and exceeded earnings estimates by $.06.
In the last 3 years, LYEL traded as high as $65.11 and as low as $7.20.
The top ETF exchange traded funds that LYEL belongs to (by Net Assets): VTI, IWM, IWN, VXF, IBB.
LYEL has underperformed the market in the last year with a return of -17.9%, while SPY returned +13.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in LYEL shares. However, LYEL has outperformed the market in the last 3 month and 2 week periods, returning +4.1% and +29.5%, while SPY returned -2.8% and -0.2%, respectively. This indicates LYEL has been having a stronger performance recently.
LYEL support price is $14.49 and resistance is $16.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LYEL shares will trade within this expected range on the day.